X4 PHARMACEUTICALS, INC Cost of Revenue
X4 PHARMACEUTICALS, INC (XFOR) reported Cost of Revenue of $1.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC cost of revenue for the quarter ending 2026-06-30 was $1.62M, a 396.01% increase year-over-year.
- X4 PHARMACEUTICALS, INC cost of revenue for the quarter ending 2026-03-31 was $598.00K, a 87.32% decline year-over-year.
- X4 PHARMACEUTICALS, INC cost of revenue for the quarter ending 2025-12-31 was $364.00K, a 20.53% increase year-over-year.
- X4 PHARMACEUTICALS, INC cost of revenue for the quarter ending 2025-09-30 was $351.00K, a 54.63% increase year-over-year.
- X4 PHARMACEUTICALS, INC cost of revenue for fiscal 2025 was $5.76M, a 622.33% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC cost of revenue for fiscal 2024 was $797.00K.
- X4 PHARMACEUTICALS, INC cost of revenue for fiscal 2023 was $0.00.
- X4 PHARMACEUTICALS, INC cost of revenue for fiscal 2022 was $0.00.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.62M 10-Q · filed 2026-08-06 | $2.21M 10-Q · filed 2026-08-06 | $2.58M derived: sum of 3 quarters · filed 2026-08-06 | $2.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $598.00K 10-Q · filed 2026-05-06 | $962.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.31M derived: sum of 3 quarters · filed 2026-05-06 | $1.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $715.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.04M derived: sum of 3 quarters · filed 2026-08-06 | $5.76M 10-K · filed 2026-03-17 |
| 2025-09-30 | $351.00K 10-Q · filed 2025-11-05 | $677.00K derived: sum of 2 quarters · filed 2026-08-06 | $5.39M 10-Q · filed 2025-11-05 | $5.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $326.00K 10-Q · filed 2026-08-06 | $5.04M 10-Q · filed 2026-08-06 | $5.34M derived: sum of 3 quarters · filed 2026-08-06 | $5.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.72M 10-Q · filed 2026-05-06 | $5.02M derived: sum of 2 quarters · filed 2026-05-06 | $5.25M derived: sum of 3 quarters · filed 2026-05-06 | $5.51M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $529.00K derived: sum of 2 quarters · filed 2026-03-17 | $797.00K derived: sum of 3 quarters · filed 2026-03-17 | $797.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $227.00K 10-Q · filed 2025-11-05 | $495.00K derived: sum of 2 quarters · filed 2025-11-05 | $495.00K 10-Q · filed 2025-11-05 | $495.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $268.00K 10-Q · filed 2025-08-08 | $268.00K 10-Q · filed 2025-08-08 | $268.00K derived: sum of 3 quarters · filed 2026-03-17 | $268.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |